Approximately 1 in 3 patients with platinum-resistant ovarian cancer will show FRα expression to qualify for therapy1. Eligibility for ELAHERE is defined as tumor tissue that shows ≥75% tumor cells staining at 2+/3+ intensity.
To support physicians in determining FOLR1/FRα status in their ovarian cancer patients, Myriad will offer FOLR1/FRα* testing through a sponsored testing program for patients with a diagnosis of epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer.
*Full name = VENTANA FOLR1 (FOLR1-2.1) RxDx Assay
Eligible patients may receive one (1) FOLR1/FRα immunohistochemistry for ovarian carcinoma at no cost regardless of test results or treatment decision. Patients must meet all of the following criteria to be eligible:
Please note the program does not cover any other costs, including, but not limited to, office fees and biopsy fees. FOLR1 will be made available broadly to prescribers without regard to prescribing volumes or other commercial considerations.
To enroll your patient in the FOLR1 IHC Testing Program, download the FOLR1 test request form.
Provider completes the test request form
Myriad Genetics receives the TRF and sends a tumor specimen collection kit to the pathology lab
Tumor sample† arrives at Myriad Genetics lab and FOLR1/FRα testing is performed
Results are sent to the ordering provider in the mail
Tumor block is returned to the pathology lab immediately after result reporting
(slides will not be returned)
†FOLR1/FRα is run on FFPE sample or tissue with 50-100 tumor nuclei present on 2 slide sections 4 microns thick, placed on unstained, unbaked, positively charged slides.